The economic burden of antibiotic resistance: A systematic review and meta-analysis.
<h4>Introduction</h4>Antibiotic resistance (ABR) has substantial global public health concerns. This systematic review aimed to synthesise recent evidence estimating the economic burden of ABR, characterised by study perspectives, healthcare settings, study design, and income of the coun...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0285170 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849469814682157056 |
|---|---|
| author | Ak Narayan Poudel Shihua Zhu Nicola Cooper Paul Little Carolyn Tarrant Matthew Hickman Guiqing Yao |
| author_facet | Ak Narayan Poudel Shihua Zhu Nicola Cooper Paul Little Carolyn Tarrant Matthew Hickman Guiqing Yao |
| author_sort | Ak Narayan Poudel |
| collection | DOAJ |
| description | <h4>Introduction</h4>Antibiotic resistance (ABR) has substantial global public health concerns. This systematic review aimed to synthesise recent evidence estimating the economic burden of ABR, characterised by study perspectives, healthcare settings, study design, and income of the countries.<h4>Methods</h4>This systematic review included peer-reviewed articles from PubMed, Medline, and Scopus databases, and grey literature on the topic of the economic burden of ABR, published between January 2016 and December 2021. The study was reported in line with 'Preferred Reporting Items for Systematic Review and Meta-Analysis' (PRISMA). Two reviewers independently screened papers for inclusion first by title, then abstract, and then the full text. Study quality was assessed using appropriate quality assessment tools. Narrative synthesis and meta-analyses of the included studies were conducted.<h4>Results</h4>A total of 29 studies were included in this review. Out of these studies, 69% (20/29) were conducted in high-income economies and the remainder were conducted in upper-and-middle income economies. Most of the studies were conducted from a healthcare or hospital perspective (89.6%, 26/29) and 44.8% (13/29) studies were conducted in tertiary care settings. The available evidence indicates that the attributable cost of resistant infection ranges from -US$2,371.4 to +US$29,289.1 (adjusted for 2020 price) per patient episode; the mean excess length of stay (LoS) is 7.4 days (95% CI: 3.4-11.4), the odds ratios of mortality for resistant infection is 1.844 (95% CI: 1.187-2.865) and readmission is 1.492 (95% CI: 1.231-1.807).<h4>Conclusion</h4>Recent publications show that the burden of ABR is substantial. There is still a lack of studies on the economic burden of ABR from low-income economies, and lower-middle-income economies, from a societal perspective, and in relation to primary care. The findings of this review may be of value to researchers, policymakers, clinicians, and those who are working in the field of ABR and health promotion.<h4>Systematic review registration</h4>CRD42020193886. |
| format | Article |
| id | doaj-art-bbaf9dd36298459a929ea8784b7137b9 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-bbaf9dd36298459a929ea8784b7137b92025-08-20T03:25:20ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01185e028517010.1371/journal.pone.0285170The economic burden of antibiotic resistance: A systematic review and meta-analysis.Ak Narayan PoudelShihua ZhuNicola CooperPaul LittleCarolyn TarrantMatthew HickmanGuiqing Yao<h4>Introduction</h4>Antibiotic resistance (ABR) has substantial global public health concerns. This systematic review aimed to synthesise recent evidence estimating the economic burden of ABR, characterised by study perspectives, healthcare settings, study design, and income of the countries.<h4>Methods</h4>This systematic review included peer-reviewed articles from PubMed, Medline, and Scopus databases, and grey literature on the topic of the economic burden of ABR, published between January 2016 and December 2021. The study was reported in line with 'Preferred Reporting Items for Systematic Review and Meta-Analysis' (PRISMA). Two reviewers independently screened papers for inclusion first by title, then abstract, and then the full text. Study quality was assessed using appropriate quality assessment tools. Narrative synthesis and meta-analyses of the included studies were conducted.<h4>Results</h4>A total of 29 studies were included in this review. Out of these studies, 69% (20/29) were conducted in high-income economies and the remainder were conducted in upper-and-middle income economies. Most of the studies were conducted from a healthcare or hospital perspective (89.6%, 26/29) and 44.8% (13/29) studies were conducted in tertiary care settings. The available evidence indicates that the attributable cost of resistant infection ranges from -US$2,371.4 to +US$29,289.1 (adjusted for 2020 price) per patient episode; the mean excess length of stay (LoS) is 7.4 days (95% CI: 3.4-11.4), the odds ratios of mortality for resistant infection is 1.844 (95% CI: 1.187-2.865) and readmission is 1.492 (95% CI: 1.231-1.807).<h4>Conclusion</h4>Recent publications show that the burden of ABR is substantial. There is still a lack of studies on the economic burden of ABR from low-income economies, and lower-middle-income economies, from a societal perspective, and in relation to primary care. The findings of this review may be of value to researchers, policymakers, clinicians, and those who are working in the field of ABR and health promotion.<h4>Systematic review registration</h4>CRD42020193886.https://doi.org/10.1371/journal.pone.0285170 |
| spellingShingle | Ak Narayan Poudel Shihua Zhu Nicola Cooper Paul Little Carolyn Tarrant Matthew Hickman Guiqing Yao The economic burden of antibiotic resistance: A systematic review and meta-analysis. PLoS ONE |
| title | The economic burden of antibiotic resistance: A systematic review and meta-analysis. |
| title_full | The economic burden of antibiotic resistance: A systematic review and meta-analysis. |
| title_fullStr | The economic burden of antibiotic resistance: A systematic review and meta-analysis. |
| title_full_unstemmed | The economic burden of antibiotic resistance: A systematic review and meta-analysis. |
| title_short | The economic burden of antibiotic resistance: A systematic review and meta-analysis. |
| title_sort | economic burden of antibiotic resistance a systematic review and meta analysis |
| url | https://doi.org/10.1371/journal.pone.0285170 |
| work_keys_str_mv | AT aknarayanpoudel theeconomicburdenofantibioticresistanceasystematicreviewandmetaanalysis AT shihuazhu theeconomicburdenofantibioticresistanceasystematicreviewandmetaanalysis AT nicolacooper theeconomicburdenofantibioticresistanceasystematicreviewandmetaanalysis AT paullittle theeconomicburdenofantibioticresistanceasystematicreviewandmetaanalysis AT carolyntarrant theeconomicburdenofantibioticresistanceasystematicreviewandmetaanalysis AT matthewhickman theeconomicburdenofantibioticresistanceasystematicreviewandmetaanalysis AT guiqingyao theeconomicburdenofantibioticresistanceasystematicreviewandmetaanalysis AT aknarayanpoudel economicburdenofantibioticresistanceasystematicreviewandmetaanalysis AT shihuazhu economicburdenofantibioticresistanceasystematicreviewandmetaanalysis AT nicolacooper economicburdenofantibioticresistanceasystematicreviewandmetaanalysis AT paullittle economicburdenofantibioticresistanceasystematicreviewandmetaanalysis AT carolyntarrant economicburdenofantibioticresistanceasystematicreviewandmetaanalysis AT matthewhickman economicburdenofantibioticresistanceasystematicreviewandmetaanalysis AT guiqingyao economicburdenofantibioticresistanceasystematicreviewandmetaanalysis |